Table 3.
MicroRNA-126 and EGFL7 as individual and combined estimates in relation to disease recurrence
| miRNA-126 and EGFL7 as individual estimates | |||
|---|---|---|---|
| Parameter | < Median | > Median | P-value* |
| miRNA-126 baseline | 10/29 = 34% | 3/28 = 11% | 0.124 |
| miRNA-126 before operation | 9/29 = 31% | 1/28 = 4% | 0.035 |
| miRNA-126 follow-up | 7/27 = 26% | 1/26 = 4% | 0.067 |
| EGFL7 baseline | 3/31 = 10% | 10/31 = 32% | 0.124 |
| EGFL7 before operation | 1/28 = 4% | 10/27 = 37% | 0.017 |
| EGFL7 follow-up | 2/28 = 7% | 7/28 = 25% | 0.161 |
| Combined estimate of miRNA-126 and EGFL7 | |||
| Sample** | miRNA-126 high + EGFL7 low | miRNA-126 low + EGFL7 high | P-value* |
| Baseline | 1/17 = 6% | 8/19 = 42% | 0.064 |
| Before operation | 0/17 = 0% | 8/16 = 50% | 0.013 |
| Follow-up | 0/12 = 0% | 4/11 = 36% | 0.106 |
EGFL7: epidermal growth factor-like domain 7; miRNA-126: microRNA-126. * Differences between the proportions are estimated using the Fisher’s Exact test. ** Only the presumed low risk (miRNA-126 high + EGFL7 low) and high risk (miRNA-126 low + EGFL7 high) groups are depicted. Ratios and percentages refer to recurrence rates